search
Back to results

The Brain Health Study: A Pragmatic, Patient-Centered Trial

Primary Purpose

Dementia, Alzheimer Disease

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Brain Health Assessment
Sponsored by
Kaiser Permanente
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Dementia

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • No prior diagnosis of dementia (defined from EHR diagnosis codes) and not receiving medications for dementia
  • Active patient at participating clinic
  • Adequate data to calculate eRADAR score

Exclusion Criteria:

- Currently receiving hospice care

Sites / Locations

  • Kaiser Permanente Northgate Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Brain Health Intervention

Usual care

Arm Description

Calculate eRADAR scores using EHR data to identify eligible individuals Invite eligible individuals for brain health assessment visit Enter results of brain health assessment visit into EHR Provide summary of results and recommended next steps to the Primary Care Physician and participant

Individuals who meet eligibility criteria will receive usual care.

Outcomes

Primary Outcome Measures

New dementia diagnoses
Rate of new dementia diagnoses identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes

Secondary Outcome Measures

Healthcare utilization
Number of primary care visits, laboratory tests performed, neuroimaging tests, and specialty visits or referrals, defined from EHR data
Dementia medications
Percent of participants who receive new medications for dementia, defined from medication orders or dispensings in the electronic health record
Urgent care/emergency department visits
Number of urgent care and emergency department visits
Hospitalizations
Number of inpatient stays
Clinic "no shows"
Number of scheduled visits missed
Medication adherence
Proportion of days covered
New dementia diagnoses (secondary definitions)
Dementia diagnosis rate in different time periods than for primary outcome, defined from EHR data
New diagnoses of mild cognitive impairment
Rate of new diagnoses of mild cognitive impairment following the intervention, defined from EHR data
Rate of accepting brain health visit
Proportion of people offered a brain health visit who accept and attend the visit
Positive predictive value of eRADAR algorithm
Proportion of people with a high risk eRADAR Score who attend a brain health visit who are diagnosed with dementia

Full Information

First Posted
April 27, 2022
Last Updated
June 13, 2023
Sponsor
Kaiser Permanente
Collaborators
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT05356702
Brief Title
The Brain Health Study: A Pragmatic, Patient-Centered Trial
Official Title
Low-cost Detection of Dementia Using Electronic Health Records Data: Validation and Testing of the eRADAR Algorithm in a Pragmatic, Patient-centered Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 6, 2022 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kaiser Permanente
Collaborators
University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.
Detailed Description
eRADAR stands for "electronic health record (EHR) Risk of Alzheimer's and Dementia Assessment Rule." It is a low-cost tool or algorithm that uses readily available EHR data elements to identify high-risk patients. We will conduct a pragmatic randomized controlled trial to assess the impact of implementing eRADAR as part of a supported outreach process on dementia detection rates. We will also explore the impact of eRADAR implementation on healthcare utilization and patient experience.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia, Alzheimer Disease

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2700 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Brain Health Intervention
Arm Type
Experimental
Arm Description
Calculate eRADAR scores using EHR data to identify eligible individuals Invite eligible individuals for brain health assessment visit Enter results of brain health assessment visit into EHR Provide summary of results and recommended next steps to the Primary Care Physician and participant
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
Individuals who meet eligibility criteria will receive usual care.
Intervention Type
Other
Intervention Name(s)
Brain Health Assessment
Intervention Description
Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
Primary Outcome Measure Information:
Title
New dementia diagnoses
Description
Rate of new dementia diagnoses identified from the electronic health record (EHR) using a prespecified set of ICD-10 codes
Time Frame
12 months after index date
Secondary Outcome Measure Information:
Title
Healthcare utilization
Description
Number of primary care visits, laboratory tests performed, neuroimaging tests, and specialty visits or referrals, defined from EHR data
Time Frame
6 months after index date
Title
Dementia medications
Description
Percent of participants who receive new medications for dementia, defined from medication orders or dispensings in the electronic health record
Time Frame
6 months after index date
Title
Urgent care/emergency department visits
Description
Number of urgent care and emergency department visits
Time Frame
1 year after index date
Title
Hospitalizations
Description
Number of inpatient stays
Time Frame
1 year after index date
Title
Clinic "no shows"
Description
Number of scheduled visits missed
Time Frame
1 year after index date
Title
Medication adherence
Description
Proportion of days covered
Time Frame
1 year after index date
Title
New dementia diagnoses (secondary definitions)
Description
Dementia diagnosis rate in different time periods than for primary outcome, defined from EHR data
Time Frame
6 months after index date; 18 months after index date
Title
New diagnoses of mild cognitive impairment
Description
Rate of new diagnoses of mild cognitive impairment following the intervention, defined from EHR data
Time Frame
12 months after index date
Title
Rate of accepting brain health visit
Description
Proportion of people offered a brain health visit who accept and attend the visit
Time Frame
3 months after invitation mailed
Title
Positive predictive value of eRADAR algorithm
Description
Proportion of people with a high risk eRADAR Score who attend a brain health visit who are diagnosed with dementia
Time Frame
12 months after index date

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: No prior diagnosis of dementia (defined from EHR diagnosis codes) and not receiving medications for dementia Active patient at participating clinic Adequate data to calculate eRADAR score Exclusion Criteria: - Currently receiving hospice care
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Leonardo Colemon, MA
Phone
206-287-2877
Email
Leonardo.X.Colemon@kp.org
First Name & Middle Initial & Last Name or Official Title & Degree
Alana Elop, MS
Phone
415-361-3602
Email
alana.elop@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sascha Dublin, MD, PhD
Organizational Affiliation
KP Washington Health Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Deborah E. Barnes, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente Northgate Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leonardo Colemon, MA
Phone
206-287-2877
Email
leonardo.x.colemon@kp.org

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
This Individual Participant Data (IPD) plan applies to all quantitative study data, such as data collected specifically for the study and those derived from electronic health records (EHR), as well as the data collected via planned study surveys, which include only short qualitative free-text fields. We do not plan to share transcripts from in-depth qualitative interviews or recorded study assessment visits. Data will be maintained on secure servers behind the firewalls at the two study sites: Kaiser Permanente Washington (KPWA) and the University of California, San Francisco (UCSF). De-identified or limited datasets containing individual-level data on which publications are based will be made available to qualified researchers for specified analyses. We will make the data available to users only under a data-use agreement (DUA).
IPD Sharing Time Frame
Data can be requested after the primary study paper is accepted for publication, up until 5 years after study completion.
IPD Sharing Access Criteria
Individuals interested in using KPWA data will be required to complete a standard form, sign a Data Use Agreement (DUA) and provide documentation of IRB approval. Data may then be accessed by qualified researchers via KPWA's Secure File Transfer (SFT) site. User registration will be required in order to access or download data files. As part of the registration process, users must agree to the conditions of use governing access to the data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgement of the data resource.
Citations:
PubMed Identifier
28849435
Citation
Lee SJ, Larson EB, Dublin S, Walker R, Marcum Z, Barnes D. A Cohort Study of Healthcare Utilization in Older Adults with Undiagnosed Dementia. J Gen Intern Med. 2018 Jan;33(1):13-15. doi: 10.1007/s11606-017-4162-3. No abstract available.
Results Reference
background
PubMed Identifier
31612463
Citation
Barnes DE, Zhou J, Walker RL, Larson EB, Lee SJ, Boscardin WJ, Marcum ZA, Dublin S. Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia. J Am Geriatr Soc. 2020 Jan;68(1):103-111. doi: 10.1111/jgs.16182. Epub 2019 Oct 14.
Results Reference
background
PubMed Identifier
34702167
Citation
Palazzo L, Hsu C, Barnes DE, Gray MF, Greenwood-Hickman MA, Larson EB, Dublin S. Patient and caregiver perspectives on a tool to increase recognition of undiagnosed dementia: a qualitative study. BMC Geriatr. 2021 Oct 26;21(1):604. doi: 10.1186/s12877-021-02523-0.
Results Reference
background

Learn more about this trial

The Brain Health Study: A Pragmatic, Patient-Centered Trial

We'll reach out to this number within 24 hrs